Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aqua Pharma appoints new vice president of Corporate Development
Crean, in the new role is expected to be responsible for all of Aqua’s acquisition, licensing and corporate initiatives. Crean joins Aqua following a senior director for Business
Crean, in the new role is expected to be responsible for all of Aqua’s acquisition, licensing and corporate initiatives. Crean joins Aqua following a senior director for Business
According to TB Alliance, the novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by
The grant covers Merrimack’s three clinical stage cancer programs, MM-121, a new, first-in-class ErbB3 (HER3) antagonist, MM-111, a new bi-specific antibody targeting ErbB2/ErbB3 (HER2/HER3) and MM-398, a nanoliposomal
The study results showed the ‘CEL-2000-DepoVax’ combination considerably lessened the symptoms and slowed the progression of RA in the animal model with a single dose. The two companies
Endo said that, the new formulation of long-acting Oxymorphone designed to be crush-resistant, is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain
The Sanford Project aims to cure T1D through the development of beta cell regeneration therapies (the cells which produce insulin in the pancreas). Under the collaboration, DiaMedica is
Boehringer said that the new findings fully support the convincing results from the RE-LY trial and show that AF patients with previous stroke or transient ischemic attack (TIA)
Santabarbara joins Infinity following five years with PharmaMar, where he most recently led the development and approval of Yondelis (trabectedin). Prior to PharmaMar, he served as vice president
Williams joins Aqua following an executive director position at Watson Pharmaceuticals, where he was responsible for brand and biologics business development since 2004. In that role, Williams developed
Hamilton will be responsible for guiding the company’s clinical programs, including the PICASSO 3 trial, an international, randomised, double-blinded, placebo-controlled trial of palifosfamide and doxorubicin in patients with